Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 8/20 | 0.36 |
| ▸ | TTR | P02766 | 7/20 | 0.36 |
| ▸ | LPL | P06858 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22816088 | 0.82 | HTR2C (0.38) | TRPV1LPLLIPGHIF1AHTR2C | |
| SCHEMBL1330907 | 0.82 | ROCK1 (0.41) | LPLLIPGHIF1AHTR2AHTR2C | |
| SCHEMBL127821 | 0.82 | FPR2 (0.43) | — | |
| SCHEMBL129403 | 0.81 | PDE4B (0.50) | — | |
| SCHEMBL14659059 | 0.80 | CSF1R (0.43) | LPLLIPGHTR2AHTR2C | |
| SCHEMBL22817145 | 0.78 | HIF1A (0.38) | TRPV1HPGDLPLLIPGHIF1A | |
| SCHEMBL14764058 | 0.78 | XDH (0.41) | — | |
| SCHEMBL23484403 | 0.77 | HIF1A (0.40) | HPGDHIF1A | |
| SCHEMBL1438849 | 0.77 | TSHR (0.38) | TRPA1TRPM8TRPV1HPGDLPL | |
| SCHEMBL16520143 | 0.76 | USP30 (0.48) | RBP4TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | TRPA1 4817/4885TRPM8 4203/4885TRPV1 4740/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | TRPA1 4817/4885TRPM8 4203/4885TRPV1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.